|
Gene: B4GALNT3 |
Gene summary for B4GALNT3 |
Gene summary. |
Gene information | Species | Human | Gene symbol | B4GALNT3 | Gene ID | 283358 |
Gene name | beta-1,4-N-acetyl-galactosaminyltransferase 3 | |
Gene Alias | B4GALNT3 | |
Cytomap | 12p13.33 | |
Gene Type | protein-coding | GO ID | GO:0005575 | UniProtAcc | Q6L9W6 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
283358 | B4GALNT3 | CCI_1 | Human | Cervix | CC | 9.15e-10 | 8.77e-01 | 0.528 |
283358 | B4GALNT3 | CCI_2 | Human | Cervix | CC | 2.36e-08 | 6.12e-01 | 0.5249 |
283358 | B4GALNT3 | CCI_3 | Human | Cervix | CC | 3.39e-04 | 5.73e-01 | 0.516 |
283358 | B4GALNT3 | HTA11_3410_2000001011 | Human | Colorectum | AD | 2.98e-17 | -6.81e-01 | 0.0155 |
283358 | B4GALNT3 | HTA11_2951_2000001011 | Human | Colorectum | AD | 4.05e-04 | -9.07e-01 | 0.0216 |
283358 | B4GALNT3 | HTA11_411_2000001011 | Human | Colorectum | SER | 3.33e-03 | 6.45e-01 | -0.2602 |
283358 | B4GALNT3 | HTA11_3361_2000001011 | Human | Colorectum | AD | 2.08e-05 | -4.57e-01 | -0.1207 |
283358 | B4GALNT3 | HTA11_866_3004761011 | Human | Colorectum | AD | 9.86e-12 | -5.88e-01 | 0.096 |
283358 | B4GALNT3 | HTA11_8622_2000001021 | Human | Colorectum | SER | 2.69e-02 | -5.85e-01 | 0.0528 |
283358 | B4GALNT3 | HTA11_7663_2000001011 | Human | Colorectum | SER | 1.09e-03 | -7.95e-01 | 0.0131 |
283358 | B4GALNT3 | HTA11_10711_2000001011 | Human | Colorectum | AD | 5.26e-07 | -6.45e-01 | 0.0338 |
283358 | B4GALNT3 | HTA11_7696_3000711011 | Human | Colorectum | AD | 3.96e-09 | -4.93e-01 | 0.0674 |
283358 | B4GALNT3 | HTA11_6818_2000001021 | Human | Colorectum | AD | 1.14e-02 | -4.99e-01 | 0.0588 |
283358 | B4GALNT3 | HTA11_99999970781_79442 | Human | Colorectum | MSS | 1.31e-27 | -7.12e-01 | 0.294 |
283358 | B4GALNT3 | HTA11_99999971662_82457 | Human | Colorectum | MSS | 4.96e-02 | -2.68e-01 | 0.3859 |
283358 | B4GALNT3 | HTA11_99999974143_84620 | Human | Colorectum | MSS | 7.14e-09 | -5.14e-01 | 0.3005 |
283358 | B4GALNT3 | F007 | Human | Colorectum | FAP | 2.34e-13 | -7.30e-01 | 0.1176 |
283358 | B4GALNT3 | A002-C-010 | Human | Colorectum | FAP | 1.24e-13 | -5.56e-01 | 0.242 |
283358 | B4GALNT3 | A001-C-207 | Human | Colorectum | FAP | 5.95e-04 | -3.80e-01 | 0.1278 |
283358 | B4GALNT3 | A015-C-203 | Human | Colorectum | FAP | 1.97e-35 | -5.95e-01 | -0.1294 |
Page: 1 2 3 4 5 6 7 8 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa00513 | Colorectum | MSS | Various types of N-glycan biosynthesis | 16/1875 | 42/8465 | 1.39e-02 | 4.53e-02 | 2.77e-02 | 16 |
hsa005131 | Colorectum | MSS | Various types of N-glycan biosynthesis | 16/1875 | 42/8465 | 1.39e-02 | 4.53e-02 | 2.77e-02 | 16 |
hsa005136 | Esophagus | ESCC | Various types of N-glycan biosynthesis | 31/4205 | 42/8465 | 1.23e-03 | 3.78e-03 | 1.93e-03 | 31 |
hsa0051313 | Esophagus | ESCC | Various types of N-glycan biosynthesis | 31/4205 | 42/8465 | 1.23e-03 | 3.78e-03 | 1.93e-03 | 31 |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
B4GALNT3 | SNV | Missense_Mutation | novel | c.1927C>G | p.Leu643Val | p.L643V | Q6L9W6 | protein_coding | tolerated(0.62) | benign(0.014) | TCGA-85-8481-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
B4GALNT3 | SNV | Missense_Mutation | novel | c.1176N>G | p.Cys392Trp | p.C392W | Q6L9W6 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-94-8490-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
B4GALNT3 | SNV | Missense_Mutation | rs142955460 | c.2078N>T | p.Arg693Leu | p.R693L | Q6L9W6 | protein_coding | deleterious(0.01) | probably_damaging(0.994) | TCGA-L3-A524-01 | Lung | lung squamous cell carcinoma | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
B4GALNT3 | SNV | Missense_Mutation | novel | c.1916N>A | p.Ser639Asn | p.S639N | Q6L9W6 | protein_coding | deleterious(0.04) | benign(0.077) | TCGA-CN-5361-01 | Oral cavity | head & neck squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
B4GALNT3 | SNV | Missense_Mutation | rs147742534 | c.271G>A | p.Glu91Lys | p.E91K | Q6L9W6 | protein_coding | tolerated(1) | benign(0) | TCGA-CN-5369-01 | Oral cavity | head & neck squamous cell carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
B4GALNT3 | SNV | Missense_Mutation | novel | c.1751N>A | p.Gly584Glu | p.G584E | Q6L9W6 | protein_coding | tolerated(0.47) | benign(0.006) | TCGA-CV-6961-01 | Oral cavity | head & neck squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | PD |
B4GALNT3 | SNV | Missense_Mutation | novel | c.2807C>T | p.Ser936Phe | p.S936F | Q6L9W6 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-CV-A463-01 | Oral cavity | head & neck squamous cell carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
B4GALNT3 | SNV | Missense_Mutation | novel | c.2621T>A | p.Ile874Asn | p.I874N | Q6L9W6 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-F7-A624-01 | Oral cavity | head & neck squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
B4GALNT3 | SNV | Missense_Mutation | c.2760N>T | p.Glu920Asp | p.E920D | Q6L9W6 | protein_coding | tolerated(0.81) | benign(0.05) | TCGA-HC-A6AO-01 | Prostate | prostate adenocarcinoma | Male | <65 | 7 | Unknown | Unknown | SD | |
B4GALNT3 | SNV | Missense_Mutation | c.1792N>T | p.Gly598Cys | p.G598C | Q6L9W6 | protein_coding | deleterious(0.01) | possibly_damaging(0.533) | TCGA-BR-4362-01 | Stomach | stomach adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |